開示情報 > FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

開示者 【45230】エーザイ株式会社
文書名 FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease  
PDF/XBRL [別ウインドウでPDFを開く]
開示日時 2021/06/08 チャネル/カテゴリ 東京証券取引所 /その他
ノート ログインするとIR文書にメモを入力して管理することができます
右上のログインメニューからログインしてください。


開示情報 > FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease